MA
CLBT icon

MYDA Advisors’s Cellebrite CLBT Stock Holding History

MYDA Advisors’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-58,200
Closed -$1.28M – 154
2024
Q4 		$1.28M Buy
+58,200
New +$1.12M 0.32% 64

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AE
Axon Enterprise Scottsdale, Arizona $19.1M AUM 8.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MYDA Advisors's CLBT Position: Q1 2025 in Review

MYDA Advisors sold out of Cellebrite (CLBT) in Q1 2025, closing a stake of 58,200 shares — an estimated $1.28M sold.

MYDA Advisors first reported a position in CLBT in Q4 2024 and held it in 1 quarter. The position peaked at $1.28M in Q4 2024. 199 funds tracked by Wall St. Rank hold CLBT as of Q1 2025.

  • MYDA Advisors reported no remaining Cellebrite position as of Q1 2025 after selling out during the quarter.
  • MYDA Advisors sold 58,200 Cellebrite shares in Q1 2025, an estimated $1.28M.
  • MYDA Advisors first reported a position in Cellebrite in Q4 2024 and held it in 1 quarter.
  • MYDA Advisors's Cellebrite position peaked at $1.28M in Q4 2024.
  • 199 funds tracked by Wall St. Rank held Cellebrite as of Q1 2025.

Based on MYDA Advisors's 13F filing for Q1 2025, filed 14 May 2025.